These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17229636)

  • 1. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma.
    Agnelli L; Bicciato S; Fabris S; Baldini L; Morabito F; Intini D; Verdelli D; Callegaro A; Bertoni F; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Haematologica; 2007 Jan; 92(1):56-65. PubMed ID: 17229636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
    Li Q; Lu Y; Wang YF; Liu XP; Qi JY; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1979-82. PubMed ID: 19950573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.
    Chiecchio L; Protheroe RK; Ibrahim AH; Cheung KL; Rudduck C; Dagrada GP; Cabanas ED; Parker T; Nightingale M; Wechalekar A; Orchard KH; Harrison CJ; Cross NC; Morgan GJ; Ross FM
    Leukemia; 2006 Sep; 20(9):1610-7. PubMed ID: 16826223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
    Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
    Facon T; Avet-Loiseau H; Guillerm G; Moreau P; Geneviève F; Zandecki M; Laï JL; Leleu X; Jouet JP; Bauters F; Harousseau JL; Bataille R; Mary JY;
    Blood; 2001 Mar; 97(6):1566-71. PubMed ID: 11238092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.
    Agnelli L; Fabris S; Bicciato S; Basso D; Baldini L; Morabito F; Verdelli D; Todoerti K; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Br J Haematol; 2007 Feb; 136(4):565-73. PubMed ID: 17367409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
    Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
    Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 14. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.
    Agnelli L; Mosca L; Fabris S; Lionetti M; Andronache A; Kwee I; Todoerti K; Verdelli D; Battaglia C; Bertoni F; Deliliers GL; Neri A
    Genes Chromosomes Cancer; 2009 Jul; 48(7):603-14. PubMed ID: 19396863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
    Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
    Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
    Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
    Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
    Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.